Journal article

HIV cure and eradication: how will we get from the laboratory to effective clinical trials?

Sharon R Lewin, Christine Rouzioux

AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2011

Abstract

Combination antiretroviral therapy (cART) has led to a major reduction in HIV-related mortality and morbidity; however, HIV can still not be cured. Achieving either a functional cure (long-term control of HIV in the absence of cART) or a sterilizing cure (elimination of all HIV-infected cells) remains a major challenge. The most significant barrier to cure is the establishment of a latent or 'silent' infection in resting CD4 T cells. Several randomized clinical trials have demonstrated that treatment intensification with additional antiretrovirals has little impact on latent reservoirs. Some potential other approaches that may reduce the latent reservoir include very early initiation of cART..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

S.R.L. is funded by the NHMRC and The Alfred Foundation. S. R. L. has also received funding for investigator initiated studies from Gilead Sciences, Merck and Cellestis Pty Ltd. C. R. is funded by the ANRS. S.R.L. is a National Health and Medical Research Council (NHMRC) of Australia practitioner fellow. This work was supported by the NHMRC, The Alfred Foundation and the ANRS (Agence Nationale de Recherches sur le Sida et les Hepatites virales). We thank Dr Paul Cameron for assistance with preparation of figures.